Chugai
Corporate brand
UnclaimedJapanese pharmaceutical company controlled by Roche and known for prescription medicines, biologics, and oncology products.
Last updated August 31, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Chugai Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company headquartered in Tokyo. Founded by Juzo Ueno in 1925 as Chugai Shinyaku Co., Ltd., the business initially imported and sold medicines before beginning its own manufacturing in 1927. It launched early products including the analgesic and antipyretic Salobrocanon in 1930, later expanding into prescription medicines, specialty therapies, oncology, immunology, and biologic drugs. The company adopted the name Chugai Pharmaceutical Co., Ltd. in 1943. Its operations were heavily affected by the destruction of its Tokyo headquarters and several factories during the Second World War, after which the company relocated its headquarters to Takada and rebuilt its manufacturing network. During the postwar period, Chugai broadened its commercial and research infrastructure. Products such as Guronsan, introduced in 1951, and Varsan, introduced in 1952, supported the company's domestic portfolio, while a public offering in 1955 and a Tokyo Stock Exchange listing in 1956 marked its development into a publicly traded pharmaceutical enterprise. Research and manufacturing expansion continued through the establishment of the Takada Research Laboratory in 1960 and new plants, including facilities at Ukima and Fujieda. Chugai also developed capabilities in chemical synthesis and biotechnology-related medicine. Its later product history includes Picibanil for cancer treatment, Epogin, the leukemia treatment Vesanoid, the antiviral Hivid, the HIV medicine Invirase, the immunosuppressant CellCept, the antiemetic Kytril, and a range of oncology products such as Xeloda, Avastin, Tarceva, Kadcyla, and Tecentriq. Chugai also launched Actemra, an interleukin-6 receptor antibody used in inflammatory diseases, and developed satralizumab, marketed as Enspryng, for neuromyelitis optica spectrum disorder. A major strategic turning point came in 2002, when Chugai began an alliance with Roche. Roche subsequently became the controlling shareholder, holding approximately 62 percent of Chugai as of June 30, 2014. The relationship gives Chugai access to Roche's international development and commercial network while preserving Chugai as a Japan-based publicly listed pharmaceutical company. Chugai has also participated in the development, production, or Japanese commercialization of Roche-associated medicines, including Tamiflu, Copegus, Avastin, Tarceva, and Tecentriq. The company has built an international presence through overseas branches and subsidiaries, including offices established in New York in 1982 and London in 1986, the acquisition of U.S.-based Gen-Probe in 1989, and the establishment of Chugai Pharma China Co., Ltd. in 2014. Its business is primarily focused on research, development, manufacturing, and commercialization of prescription medicines rather than consumer software or general information technology. Core therapeutic interests include oncology, immunology, hematology, infectious disease, and rare or neurologic disorders. Chugai's public profile is particularly associated with innovative biologics and specialty medicines developed through collaboration with Roche and other research partners.
History
Chugai Pharmaceutical traces its origins to 1925, when Juzo Ueno founded Chugai Shinyaku Co., Ltd. in Japan to import and sell medicines. The company moved into proprietary manufacturing in 1927 and launched Salobrocanon, an analgesic and antipyretic, in 1930. Its early portfolio expanded into products such as calcium bromide, Guronsan, and Varsan. In 1943, the company adopted the name Chugai Pharmaceutical Co., Ltd. The Second World War caused extensive disruption. Chugai's headquarters and factories in Ikebukuro, Sakai, and Takada were destroyed or damaged, prompting the relocation of the headquarters to Takada and the rebuilding of production facilities. A further plant was constructed at Kamagiishi in 1946. The company resumed expansion during the postwar reconstruction period and became publicly held in 1955. Its shares were listed on the Tokyo Stock Exchange in 1956. Chugai developed a more substantial research and industrial base during the 1950s and 1960s. It built the Ukima plant in 1957 and opened the Takada Research Laboratory in Tokyo in 1960. The company also worked on vitamin A synthesis patents and expanded its chemical and manufacturing activities through affiliated companies, including the business that became Eiko Kasei. A Fujieda factory was added in 1971. The oncology medicine Picibanil, launched in 1975, illustrated the company's increasing emphasis on prescription and specialist therapies. Internationalization became more visible from the 1980s onward. Chugai opened branches in New York in 1982 and London in 1986, and acquired Gen-Probe Incorporated in the United States in 1989. During the 1990s and early 2000s, it introduced or participated in the development and commercialization of medicines across oncology, hematology, transplantation, infectious disease, and supportive care. Products associated with this period included Epogin, Vesanoid, Hivid, Invirase, CellCept, Kytril, and Tamiflu. The 2002 alliance with Roche was the company's most important modern strategic development. The partnership connected Chugai's Japanese research and commercial operations with Roche's global pharmaceutical network. Chugai subsequently launched or produced several Roche-associated medicines in Japan and other markets, including Xeloda, Copegus, Avastin, Tarceva, and Tecentriq. Chugai also developed its own important biologic franchises, notably Actemra, an interleukin-6 receptor antibody used in rheumatoid arthritis and other inflammatory conditions, and satralizumab, later marketed as Enspryng for neuromyelitis optica spectrum disorder. Roche became Chugai's controlling shareholder, owning approximately 62 percent as of June 30, 2014. Chugai nevertheless remained a separately listed Japanese pharmaceutical company with its own management and research identity. The company established Chugai Pharma China Co., Ltd. in 2014 and continued to pursue academic and biotechnology collaborations, including cooperation with Osaka University in 2016. Its present brand identity is centered on innovative prescription medicines, biologics, oncology, immunology, hematology, and treatments for rare or neurologic diseases. The available reference material does not provide a complete account of later management changes, financial performance, or the full scope of Chugai's current product portfolio.
- 2020
Enspryng approved in the United States
[1]The FDA approved satralizumab, marketed as Enspryng, for neuromyelitis optica spectrum disorder.
- 2018
Tecentriq launched
[1]Chugai launched Tecentriq, an oncology medicine associated with Roche.
- 2014
Chugai Pharma China established
[1]Chugai established Chugai Pharma China Co., Ltd.
- 2005
Actemra launched
[1]Chugai launched Actemra, an interleukin-6 receptor antibody for inflammatory disease treatment.
- 2002
Roche alliance begins
[1]Chugai began its strategic alliance with Roche.
- 1989
Gen-Probe acquired
[1]Chugai acquired Gen-Probe Incorporated in the United States.
- 1986
London branch opened
[1]Chugai opened a London branch as part of its international expansion.
- 1982
New York branch opened
[1]Chugai expanded its overseas presence by opening a branch in New York.
- 1975
Picibanil launched
[1]Chugai launched Picibanil, a medicine used in cancer treatment.
- 1960
Research center established
[1]Chugai established the Takada Research Laboratory in Tokyo.
Products and positioning
Research-driven Japanese pharmaceutical company focused on specialty medicines, biologics, oncology, immunology, and rare diseases, with Roche as its controlling corporate partner.
Immunology biologic · 2005
Actemra
Actemra is Chugai's interleukin-6 receptor monoclonal antibody. It became a major biologic product in the company's portfolio and is associated with treatment of rheumatoid arthritis and other inflammatory conditions. The product reflects Chugai's emphasis on antibody-based medicines and its collaboration with Roche.
Hematology medicine · 1990
Epogin
Epogin is an erythropoietin-related medicine introduced by Chugai in 1990. It belongs to the company's hematology and supportive-care heritage and represents the expansion of Chugai's portfolio beyond traditional small-molecule medicines into biologically derived therapies.
Oncology medicine · 2014
Kadcyla
Kadcyla is an oncology product launched by Chugai in 2014. It is associated with the Roche partnership and illustrates Chugai's role in bringing advanced cancer therapies into its commercial portfolio.
Oncology immunotherapy · 2018
Tecentriq
Tecentriq is an oncology medicine launched by Chugai in 2018. Its inclusion in the portfolio demonstrates the company's focus on contemporary cancer immunotherapy and the importance of Roche-linked products to its commercial activities.
Neurology and rare-disease biologic · 2020
Enspryng
Enspryng is the brand name for satralizumab, an antibody medicine approved by the U.S. Food and Drug Administration in 2020 for neuromyelitis optica spectrum disorder. It represents Chugai's work in rare and neurologic diseases.
Antiviral medicine · 2001
Tamiflu
Chugai produced Tamiflu, an antiviral medicine developed within the Roche network. The product is an example of Chugai's manufacturing and commercialization role in medicines developed through international pharmaceutical collaboration.
Oncology medicine · 1975
Picibanil
Picibanil was launched in 1975 as a cancer medicine. It is one of the earlier specialist products associated with Chugai's transition toward a prescription-pharmaceutical portfolio with a significant oncology presence.
Brand decisions
2016
Cooperation with Osaka UniversityStrategyBackground
Chugai continued to develop links with academic institutions to support research and innovation.
Action taken
The company began a cooperation initiative with Osaka University.
Aftermath
The cooperation strengthened Chugai's connection with Japanese academic research, while the available source does not describe specific resulting products.
2015
Japanese co-commercialization agreement for stroke cell therapyStrategyBackground
Chugai pursued opportunities in regenerative medicine and advanced therapies for ischemic stroke.
Action taken
Chugai announced an agreement to co-commercialize an Athersys stem-cell therapy in Japan.
Aftermath
The arrangement was reported as potentially capable of generating more than US$205 million, but the available reference does not specify realized revenue or the ultimate commercial outcome.
Potential value. More than US$205 million (2015 announcement)
2014
Establishment of Chugai Pharma ChinaStrategyBackground
Chugai continued expanding its presence in Asian pharmaceutical markets.
Action taken
The company founded Chugai Pharma China Co., Ltd.
Aftermath
The new subsidiary extended Chugai's organizational presence in China, although the available reference does not provide detailed operating or financial results.
2002
Strategic alliance with RocheStrategyBackground
Chugai sought to strengthen its international pharmaceutical capabilities and connect its Japanese research and commercial base with a global partner.
Action taken
Chugai entered a strategic alliance with Roche, which later became the company's controlling shareholder.
Aftermath
The alliance supported joint or linked development and commercialization of multiple medicines and made Roche the dominant corporate partner in Chugai's ownership structure.
Recent events
Fresenius filed patent review petitions challenging rheumatoid arthritis patents[2]
Fresenius Kabi USA and Fresenius Kabi SwissBioSim filed Inter Partes Review petitions challenging two patents assigned to Chugai, Roche, and Genentech, asserting that the relevant claims were invalid as anticipated or obvious. These are allegations in the petitions, not a reported decision on their merits.
Sources2 sources
Cite this profile: Cite the canonical profile. /brand-wiki/chugai · Editorial policy · How profiles are compiled